COMMUNIQUÉS West-GlobeNewswire

Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today
08/06/2026
Multiple EULAR presentations reinforce potential of AlloNK to drive deep B-cell depletion and meaningful clinical responses across refractory rheumatoid arthritis, Sjögren disease and systemic sclerosis Late-breaking [...]
Aclarion Stockholders Approve All Proposals at 2026 Annual Meeting
08/06/2026
BROOMFIELD, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc ., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW) , a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary [...]
Engitix Announces Strategic Collaboration with GSK to Advance First-in-Class Targets for Liver Fibrosis Regression
08/06/2026
Collaboration leverages Engitix’s human ECM Platform to identify high-confidence targets for liver fibrosis regression LONDON, June 08, 2026 (GLOBE NEWSWIRE) -- Engitix Ltd. (“Engitix”), a biotechnology company [...]
Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer
08/06/2026
Initial data from ongoing Phase 1/2 trial in patients with second and third line PDAC treated with vopimetostat and daraxonrasib showed 6-month PFS rate of 90% (median PFS not yet reached) suggesting durability of [...]
Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)
08/06/2026
Late-breaking presentation reports a proteomic analysis of heart failure biomarkers during lorundrostat treatment RADNOR, Pa., June 08, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a [...]
Medicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission
08/06/2026
European regulatory filing supports planned 2026 initiation of Phase 2b study of Teverelix® in an underserved population representing ~$4 billion annual market opportunity PHILADELPHIA, June 08, 2026 (GLOBE NEWSWIRE [...]
Virbac : Declaration of the number of shares and voting rights 05/2026
08/06/2026
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]
Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion
08/06/2026
Gastrointestinal prophylaxis reduced Grade ≥ 2 diarrhea/colitis from 55% without prophylaxis to 10% with prophylaxis The maximum tolerated dose has not yet been determined No difference is observed in GCC CAR T-cell [...]
Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. Lives
08/06/2026
Agreement with second leading group purchasing organization (GPO), effective June 1, 2026, provides access to approximately 17 million additional U.S. commercial lives (10% of the ~177 million commercial lives in the U. [...]
Shattuck Labs Announces Phase 1 Results for SL-325
08/06/2026
Potentially best-in-mechanism immunogenicity profile, with only 3.7% of participants developing antidrug antibodies Complete blockade of TL1A binding to DR3 for over 3 months expected at doses of 1 mg/kg and higher Well [...]
Sequel Presents Pivotal Trial of the twiist™ Automated Insulin Delivery System in Adults with Insulin-Treated Type 2 Diabetes at the ADA 86th Scientific Sessions
08/06/2026
Investigational study marks Sequel’s first pivotal data in type 2 diabetes, the largest population on insulin therapy and one of the most under-served by automated insulin delivery NEW ORLEANS, June 08, 2026 (GLOBE [...]
Aclarion Rejects Echo Lake Capital’s Unsolicited Acquisition Proposal
08/06/2026
BROOMFIELD, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc. , (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW) , a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary [...]
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine
08/06/2026
– All 12 patients in study (100%) achieved insulin independence, producing their own insulin and no longer requiring exogenous insulin therapy to manage their T1D – All 12 patients also achieved an HbA1c below 6.5%, [...]
Standard BioTools and Treeline Biosciences Announce Merger Agreement
08/06/2026
Combined company to operate as Treeline Biosciences, advancing a deep pipeline of small molecule inhibitors, protein degraders and targeted therapy antibody-drug conjugates Company to be led by Treeline CEO and co- [...]
Virbac : Déclaration d'actions et de droits de vote 05/2026
08/06/2026
DÉCLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) [...]
Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses
08/06/2026
KT-579 demonstrated consistent disease-modifying activity comparable or superior to approved and clinically active therapies in multiple preclinical lupus models KT-579 Phase 1 healthy volunteer trial ongoing, with data [...]
Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance
08/06/2026
MINNEAPOLIS and BRISBANE, Australia, June 08, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) announced today that it has received full regulatory [...]
Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program
08/06/2026
Program to Provide Donations to Non-Profit Organizations Aligned with Corporate Values Deadline for Applications is August 3, 2026 SOUTH SAN FRANCISCO, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, [...]
Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026
08/06/2026
WALTHAM, Mass., June 08, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today [...]

Pages